Abdulrahman Nasiri: A New Perspective on Avatrombopag in Aplastic Anemia
Abdulrahman Nasiri, Assistant Professor of Medicine and Hematology at Imam Mohammad Ibn Saud Islamic University, shared on LinkedIn:
“Kicking off 2026: A New Perspective on Avatrombopag in Aplastic Anemia
I am pleased to start the new year by sharing our latest review article, published in Therapeutic Advances in Hematology.
While Thrombopoietin Receptor Agonists (TPO-RAs) like Eltrombopag have revolutionized the treatment of Aplastic Anemia (AA), hepatotoxicity and dietary restrictions remain significant challenges for many patients.
Our team conducted a comprehensive review of clinical evidence from 2023 to 2025 to evaluate the efficacy and safety of Avatrombopag (AVA) as an alternative.
Key Findings for Clinical Practice:
- High Efficacy: Across the reviewed studies, we observed Overall Response Rates (ORR) ranging from 55% to 85%, with complete response rates reaching up to one-third of treated patients.
- Superior Liver Safety: Unlike earlier agents in this class, Avatrombopag demonstrated a favorable safety profile with no clinically relevant hepatotoxicity reported. It appears safe even for patients with underlying liver dysfunction.
- Rapid Response: Hematologic improvement typically occurred within 1–2 months, aligning well with clinical decision-making timelines.
- Patient Convenience: AVA requires no dietary restrictions and does not undergo significant hepatic metabolism, simplifying management for complex patients.
Title: Efficacy and safety of avatrombopag in aplastic anemia: a comprehensive review of clinical evidence
I extend my sincere gratitude to Dr. Mostafa Faisal Mohammed Saleh, Dr. Ahmed Kotb Abdrabou, Dr. Alfadil Haroon, Dr. Hadeel Samarkandi, Dr. Hazza Alzahrani, Dr. Mahmoud Aljurf, Dr. Ali Alahmari.
Read the full review here.”
Stay updated with Hemostasis Today.
-
Feb 24, 2026, 14:31Augustina Isioma Ikusemoro: What Happens After You Donate Blood?
-
Feb 24, 2026, 14:27Eloïse Laouenan: Rising Risk of Pregnancy Related Venous Thromboembolism
-
Feb 24, 2026, 14:01A European Action Plan on Rare Diseases Is a Necessity, Not an Option – EPODIN
-
Feb 24, 2026, 13:59Riitta Lassila: How APAC Impacts the Interplay Between Complement and Coagulation
-
Feb 24, 2026, 13:29Win Ratio Analysis of Edoxaban vs Dalteparin in Cancer-Associated VTE – JTH
-
Feb 24, 2026, 13:28EAHAD Welcomes New Members to the Nurses Committee
-
Feb 24, 2026, 13:25AbQader Bedil: Donor Ferritin Testing and Iron Care
-
Feb 24, 2026, 12:53Tagreed Alkaltham։ Blood Is a Naturally Integrated and Adaptive Physiological System
-
Feb 23, 2026, 18:13Fight4Hematology Supports Research and Empowers the Next Generation – ASH